Aeterna Zentaris (AEZS) 1.18 $AEZS
Traders Get Bullish on Shares of AEterna Zentaris, Shares Up 6.6% (AEZS)
Comtex SmarTrend(R) - Wed Jul 02, 10:09AM CDT
AEterna Zentaris (NASDAQ:AEZS) is one of today's best performing low-priced stocks, up 6.6% to $1.29 on 7.0x average daily volume. AEterna Zentaris has traded 2.7 million shares thus far today, vs. average volume of 386,000 shares per day. The stock has outperformed the Dow (6.6% to the Dow's 0.1%) and outperformed the S&P 500 (6.6% to the S&P's 0.1%) during today's trading.
Chronic Urticaria Or Hives - Pipeline Review, H1 2014
M2 - Fri Jun 27, 5:30AM CDT
Research and Markets (http://www.researchandmarkets.com/research/nwxvjx/chronic_urticaria) has announced the addition of the "Chronic Urticaria Or Hives - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Chronic Urticaria Or Hives, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Urticaria Or Hives and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Chronic Urticaria Or Hives - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Chronic Urticaria Or Hives pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope Companies Mentioned: - Bristol-Myers Squibb Company - F. Hoffmann-La Roche Ltd. - AstraZeneca PLC - Genentech, Inc. - Merck & Co., Inc. - Biofrontera AG - AEterna Zentaris Inc. - ELORAC, Inc. For more information visit http://www.researchandmarkets.com/research/nw..._urticaria
Aeterna Zentaris to Present at Upcoming Bloom Burton & Co. Healthcare Investor Conference in Toronto
CNW Group - Wed Jun 11, 6:30AM CDT
Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company"
today announced that the Company's Chairman, CEO, David Dodd, will be presenting a corporate overview at the Bloom Burton & Co. Healthcare Investor Conference on Wednesday, June 18, 2014, at 11:30 am (Eastern), in Room A-B, 4(th) floor of the Toronto Board of Trade in Toronto, Canada.
Aeterna Zentaris Implements Global Resources Optimization Program as Part of its Transition into a Commercially Operating Specialty Biopharmaceutical Company
CNW Group - Tue Jun 10, 6:30AM CDT
Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company" today announced the roll-out of a global resources optimization program as the Company pursues its strategy of transitioning into a commercially operating specialty biopharmaceutical company. Initiated earlier this year, the program's goal is to streamline R&D activities and increase commercial operations and flexibility. With the implementation of the global resources optimization program, the Company expects to have approximately 65 employees by year-end, as compared to 90 employees at the beginning of 2014. Due to the nature of certain proceedings, the Company intends to provide an estimate of the anticipated global restructuring charges and future cost savings as and when the financial and accounting implications of the global resources optimization program become better defined.
Aeterna Zentaris: Poster Presented at ASCO Meeting on the Design of the Current ZoptEC Phase 3 Trial in Endometrial Cancer
PR Newswire - Mon Jun 02, 6:30AM CDT
Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX:AEZ) (the "Company" today announced that a poster was presented on the design of its current ZoptEC (Zoptarelin doxorubicin in Endometrial Cancer) Phase 3 trial in women with advanced, recurrent or metastatic endometrial cancer. The poster #TPS5630 titled, "ZoptEC: Phase 3 study of zoptarelin doxorubicin (AEZS-108)in platinum-taxane pretreated endometrial cancer (Study AEZS-108-050)", D.S.Miller, H. Gabra, G. Emons, D. S. McMeekin, A. M. Oza, S. M. Temkin, I. Vergote, was presented over the weekend by lead investigator, David S. Miller, MD, of the University of Texas Southwestern Medical Center, in Dallas, during the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago. Currently, more than 100 sites are in operation and some160 patients have been recruited for this ZoptEC Phase 3 trial.
Aeterna Zentaris: Poster to be Presented on the Design of Current ZoptEC Phase 3 Trial in Endometrial Cancer with Zoptarelin Doxorubicin at ASCO
CNW Group - Thu May 22, 6:30AM CDT
Aeterna Zentaris Inc. (NASDAQ: AEZS, TSX: AEZ) (the "Company" today announced that a poster will be presented on the design of its current ZoptEC (Zoptarelin doxorubicin in Endometrial Cancer) Phase 3 trial in women with advanced, recurrent or metastatic endometrial cancer. The poster will be presented by lead investigator, David S. Miller MD, of the University of Texas Southwestern Medical Center in Dallas, during the 50(th) Annual Meeting of the American Society of Clinical Oncology (ASCO), to be held May 30-June 4, 2014 in Chicago. There are currently over 100 sites in operation and over 150 patients have been recruited for this ZoptEC Phase 3 trial.
Aeterna Zentaris Announces Board of Directors Leadership Change and Election of Directors at Annual Meeting of Shareholders
PR Newswire - Mon May 12, 6:30AM CDT
Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company" announces that following its annual meeting of shareholders held on May 9, 2014, its Board of Directors has appointed current President and CEO, David Dodd, as Chairman of the Board, a decision that is in keeping with Aeterna Zentaris' new strategy of transitioning from a research and development into a commercial company. The Board believes that with both roles being assumed by David Dodd, the decision-making process of the leadership will be more efficient, which should also accelerate the attainment of the Company's objective of becoming a commercial entity. In order to ensure that the Board of Directors will continue to act independently from management, Juergen Ernst, former Chairman of the Board and an independent director, will assume the role of Lead Director.
Aeterna Zentaris Announces At the Market Issuance Program
CNW Group - Fri May 09, 3:15PM CDT
Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company" announced today that it has entered into an At Market Issuance ("ATM" Sales Agreement, dated May 9, 2014, with MLV & Co. LLC ("MLV" , under which the Company may, at its discretion, from time to time during the term of the sales agreement, sell up to a maximum of 14,018,692 million of its common shares through ATM issuances on the NASDAQ Stock Market, up to an aggregate amount of US $15 million. MLV will act as sales agent for any sales made under the ATM. The common shares will be sold at market prices prevailing at the time of the sale of common shares, and, as a result, prices may vary.
Aeterna Zentaris Reports First Quarter 2014 Financial and Operating Results
CNW Group - Thu May 08, 3:30PM CDT
All amounts are in US dollars
Breast Cancer - Pipeline Review, H1 2014: 269 Companies Profiled
M2 - Thu May 08, 3:33AM CDT
Research and Markets (http://www.researchandmarkets.com/research/5jqqdb/breast_cancer) has announced the addition of the "Breast Cancer - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Breast Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Breast Cancer and special features on late-stage and discontinued projects. Scope - The report provides a snapshot of the global therapeutic landscape of Breast Cancer - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Breast Cancer and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Breast Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Breast Cancer pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Mentioned: - 3-V Biosciences, Inc. - A&G Pharmaceutical, Inc. - A. Menarini Industrie Farmaceutiche Riunite Srl - AEterna Zentaris Inc. - AbbVie Inc. - Actinium Pharmaceuticals, Inc. - Advanced Cancer Therapeutics - Advaxis, Inc. - Advenchen Laboratories, LLC - Aegis Therapeutics, LLC - Affichem - Aileron Therapeutics, Inc. - Alchemia Limited - Alethia Biotherapeutics Inc. - Algeta ASA - Almac Discovery Ltd. - AlphaMab Co., Ltd - AlphaVax, Inc. - Ambrx, Inc. - Amgen Inc. - Ampio Pharmaceuticals, Inc. - Amplyx Pharmaceuticals, Inc. - Angion Biomedica Corp. - AntiCancer, Inc. - Antigen Express, Inc. - Antyra, Inc. - Aphios Corporation - Armour Therapeutics Inc. - Arno Therapeutics, Inc. - Arrien Pharmaceuticals, LLC For more information visit http://www.researchandmarkets.com/research/5j...ast_cancer
Neuroblastoma Pipeline Review 2014: 32 Companies & 73 Drug profiles
M2 - Wed May 07, 9:44AM CDT
Research and Markets (http://www.researchandmarkets.com/research/9pzz2k/neuroblastoma) has announced the addition of the "Neuroblastoma - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Neuroblastoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Neuroblastoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Neuroblastoma - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Neuroblastoma and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Neuroblastoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Neuroblastoma pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Involved in Therapeutics Development - United Therapeutics Corporation - Shionogi & Co., Ltd. - GlaxoSmithKline plc - Gamida Cell Ltd. - BioLineRx, Ltd. - Novartis AG - Chugai Pharmaceutical Co., Ltd. - Teva Pharmaceutical Industries Limited - Progenics Pharmaceuticals, Inc. - Celgene Corporation - AEterna Zentaris Inc. - Lixte Biotechnology Holdings, Inc. - Lorus Therapeutics Inc. - Novogen Limited - Threshold Pharmaceuticals, Inc. - Sareum Holdings plc - MabVax Therapeutics, Inc. - Bionucleon Srl - CerRx, Inc. - Merrimack Pharmaceuticals, Inc. - Neotropix, Inc. - APEIRON Biologics AG - Xcovery, Inc. - Sutro Biopharma, Inc. - Incuron, LLC - Errant Gene Therapeutics, LLC - DEKK-TEC, Inc. - Bexion Pharmaceuticals, LLC. - Cancer Prevention Pharmaceuticals, Inc. - CureFAKtor Pharmaceuticals. LLC For more information visit http://www.researchandmarkets.com/research/9p...roblastoma
Endometrial Cancer - Pipeline Review, H1 2014: 24 Company and 37 Drugs Profiled
M2 - Wed May 07, 9:00AM CDT
Research and Markets (http://www.researchandmarkets.com/research/w7hgnd/endometrial) has announced the addition of the "Endometrial Cancer - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Endometrial Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Endometrial Cancer and special features on late-stage and discontinued projects. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Companies Involved: - AEterna Zentaris Inc. - Acceleron Pharma, Inc. - ArQule, Inc. - Ariad Pharmaceuticals, Inc. - Arno Therapeutics, Inc. - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - Critical Outcome Technologies Inc. - Eisai Co., Ltd. - Esperance Pharmaceuticals, Inc. - Exelixis, Inc. - Galena Biopharma, Inc. - GlaxoSmithKline plc - Igenica, Inc. - ImmunoGen, Inc. - Ipsen S.A. - Merck & Co., Inc. - Novartis AG - OncoHoldings, Inc. - Oryzon Genomics S.A. - Pfizer Inc. - Pharmsynthez - Scancell Holdings Plc - Taiho Pharmaceutical Co., Ltd. Drug Profiles: - zoptarelin doxorubicin - ixabepilone - lenvatinib - MK-2206 - PF-05212384 - ridaforolimus - dalantercept - cabozantinib (s)-malate - nintedanib - EP-100 - dovitinib lactate - buparlisib hydrochloride - Virexxa - GALE-301 - GSK-2636771 - GSK-2141795 - GSK-2256098 - GSK-2141795 trametinib - IMGN-853 - ARQ-092 - onapristone ER - COTI-2 - EP-200 - ONCO-101 - TAS-2985 - SERD 2 - (ponatinib ridaforolimus) - Virexxa - Monoclonal Antibody For Endometrial Cancer - Small Molecules for Oncology and Infectious Disease For more information visit http://www.researchandmarkets.com/research/w7hgnd/endometria
Aeterna Zentaris to Present Poster on New Therapeutic Opportunities in Oncology with Erk Inhibitors at AACR Meeting in San Diego
CNW Group - Tue Apr 01, 6:30AM CDT
Aeterna Zentaris Inc. (NASDAQ: AEZS, TSX: AEZ) (the "Company" today announced that a poster will be presented on AEZS-134, a highly potent and selective ATP competitive Erk inhibitor, during the American Association for Cancer Research (AACR) Annual Meeting, which will be held April 5-9, 2014 in San Diego, California.
Traders Get Bullish on Shares of AEterna Zentaris, Shares Up 6.6% (AEZS)
Comtex SmarTrend(R) - Wed Jul 02, 10:09AM CDT
AEterna Zentaris (NASDAQ:AEZS) is one of today's best performing low-priced stocks, up 6.6% to $1.29 on 7.0x average daily volume. AEterna Zentaris has traded 2.7 million shares thus far today, vs. average volume of 386,000 shares per day. The stock has outperformed the Dow (6.6% to the Dow's 0.1%) and outperformed the S&P 500 (6.6% to the S&P's 0.1%) during today's trading.
Chronic Urticaria Or Hives - Pipeline Review, H1 2014
M2 - Fri Jun 27, 5:30AM CDT
Research and Markets (http://www.researchandmarkets.com/research/nwxvjx/chronic_urticaria) has announced the addition of the "Chronic Urticaria Or Hives - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Chronic Urticaria Or Hives, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Urticaria Or Hives and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Chronic Urticaria Or Hives - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Chronic Urticaria Or Hives pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope Companies Mentioned: - Bristol-Myers Squibb Company - F. Hoffmann-La Roche Ltd. - AstraZeneca PLC - Genentech, Inc. - Merck & Co., Inc. - Biofrontera AG - AEterna Zentaris Inc. - ELORAC, Inc. For more information visit http://www.researchandmarkets.com/research/nw..._urticaria
Aeterna Zentaris to Present at Upcoming Bloom Burton & Co. Healthcare Investor Conference in Toronto
CNW Group - Wed Jun 11, 6:30AM CDT
Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company"
today announced that the Company's Chairman, CEO, David Dodd, will be presenting a corporate overview at the Bloom Burton & Co. Healthcare Investor Conference on Wednesday, June 18, 2014, at 11:30 am (Eastern), in Room A-B, 4(th) floor of the Toronto Board of Trade in Toronto, Canada. Aeterna Zentaris Implements Global Resources Optimization Program as Part of its Transition into a Commercially Operating Specialty Biopharmaceutical Company
CNW Group - Tue Jun 10, 6:30AM CDT
Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company"
today announced the roll-out of a global resources optimization program as the Company pursues its strategy of transitioning into a commercially operating specialty biopharmaceutical company. Initiated earlier this year, the program's goal is to streamline R&D activities and increase commercial operations and flexibility. With the implementation of the global resources optimization program, the Company expects to have approximately 65 employees by year-end, as compared to 90 employees at the beginning of 2014. Due to the nature of certain proceedings, the Company intends to provide an estimate of the anticipated global restructuring charges and future cost savings as and when the financial and accounting implications of the global resources optimization program become better defined. Aeterna Zentaris: Poster Presented at ASCO Meeting on the Design of the Current ZoptEC Phase 3 Trial in Endometrial Cancer
PR Newswire - Mon Jun 02, 6:30AM CDT
Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX:AEZ) (the "Company"
today announced that a poster was presented on the design of its current ZoptEC (Zoptarelin doxorubicin in Endometrial Cancer) Phase 3 trial in women with advanced, recurrent or metastatic endometrial cancer. The poster #TPS5630 titled, "ZoptEC: Phase 3 study of zoptarelin doxorubicin (AEZS-108)in platinum-taxane pretreated endometrial cancer (Study AEZS-108-050)", D.S.Miller, H. Gabra, G. Emons, D. S. McMeekin, A. M. Oza, S. M. Temkin, I. Vergote, was presented over the weekend by lead investigator, David S. Miller, MD, of the University of Texas Southwestern Medical Center, in Dallas, during the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago. Currently, more than 100 sites are in operation and some160 patients have been recruited for this ZoptEC Phase 3 trial. Aeterna Zentaris: Poster to be Presented on the Design of Current ZoptEC Phase 3 Trial in Endometrial Cancer with Zoptarelin Doxorubicin at ASCO
CNW Group - Thu May 22, 6:30AM CDT
Aeterna Zentaris Inc. (NASDAQ: AEZS, TSX: AEZ) (the "Company"
today announced that a poster will be presented on the design of its current ZoptEC (Zoptarelin doxorubicin in Endometrial Cancer) Phase 3 trial in women with advanced, recurrent or metastatic endometrial cancer. The poster will be presented by lead investigator, David S. Miller MD, of the University of Texas Southwestern Medical Center in Dallas, during the 50(th) Annual Meeting of the American Society of Clinical Oncology (ASCO), to be held May 30-June 4, 2014 in Chicago. There are currently over 100 sites in operation and over 150 patients have been recruited for this ZoptEC Phase 3 trial. Aeterna Zentaris Announces Board of Directors Leadership Change and Election of Directors at Annual Meeting of Shareholders
PR Newswire - Mon May 12, 6:30AM CDT
Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company"
announces that following its annual meeting of shareholders held on May 9, 2014, its Board of Directors has appointed current President and CEO, David Dodd, as Chairman of the Board, a decision that is in keeping with Aeterna Zentaris' new strategy of transitioning from a research and development into a commercial company. The Board believes that with both roles being assumed by David Dodd, the decision-making process of the leadership will be more efficient, which should also accelerate the attainment of the Company's objective of becoming a commercial entity. In order to ensure that the Board of Directors will continue to act independently from management, Juergen Ernst, former Chairman of the Board and an independent director, will assume the role of Lead Director. Aeterna Zentaris Announces At the Market Issuance Program
CNW Group - Fri May 09, 3:15PM CDT
Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company"
announced today that it has entered into an At Market Issuance ("ATM" Sales Agreement, dated May 9, 2014, with MLV & Co. LLC ("MLV" , under which the Company may, at its discretion, from time to time during the term of the sales agreement, sell up to a maximum of 14,018,692 million of its common shares through ATM issuances on the NASDAQ Stock Market, up to an aggregate amount of US $15 million. MLV will act as sales agent for any sales made under the ATM. The common shares will be sold at market prices prevailing at the time of the sale of common shares, and, as a result, prices may vary. Aeterna Zentaris Reports First Quarter 2014 Financial and Operating Results
CNW Group - Thu May 08, 3:30PM CDT
All amounts are in US dollars
Breast Cancer - Pipeline Review, H1 2014: 269 Companies Profiled
M2 - Thu May 08, 3:33AM CDT
Research and Markets (http://www.researchandmarkets.com/research/5jqqdb/breast_cancer) has announced the addition of the "Breast Cancer - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Breast Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Breast Cancer and special features on late-stage and discontinued projects. Scope - The report provides a snapshot of the global therapeutic landscape of Breast Cancer - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Breast Cancer and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Breast Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Breast Cancer pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Mentioned: - 3-V Biosciences, Inc. - A&G Pharmaceutical, Inc. - A. Menarini Industrie Farmaceutiche Riunite Srl - AEterna Zentaris Inc. - AbbVie Inc. - Actinium Pharmaceuticals, Inc. - Advanced Cancer Therapeutics - Advaxis, Inc. - Advenchen Laboratories, LLC - Aegis Therapeutics, LLC - Affichem - Aileron Therapeutics, Inc. - Alchemia Limited - Alethia Biotherapeutics Inc. - Algeta ASA - Almac Discovery Ltd. - AlphaMab Co., Ltd - AlphaVax, Inc. - Ambrx, Inc. - Amgen Inc. - Ampio Pharmaceuticals, Inc. - Amplyx Pharmaceuticals, Inc. - Angion Biomedica Corp. - AntiCancer, Inc. - Antigen Express, Inc. - Antyra, Inc. - Aphios Corporation - Armour Therapeutics Inc. - Arno Therapeutics, Inc. - Arrien Pharmaceuticals, LLC For more information visit http://www.researchandmarkets.com/research/5j...ast_cancer
Neuroblastoma Pipeline Review 2014: 32 Companies & 73 Drug profiles
M2 - Wed May 07, 9:44AM CDT
Research and Markets (http://www.researchandmarkets.com/research/9pzz2k/neuroblastoma) has announced the addition of the "Neuroblastoma - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Neuroblastoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Neuroblastoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Neuroblastoma - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Neuroblastoma and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Neuroblastoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Neuroblastoma pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Involved in Therapeutics Development - United Therapeutics Corporation - Shionogi & Co., Ltd. - GlaxoSmithKline plc - Gamida Cell Ltd. - BioLineRx, Ltd. - Novartis AG - Chugai Pharmaceutical Co., Ltd. - Teva Pharmaceutical Industries Limited - Progenics Pharmaceuticals, Inc. - Celgene Corporation - AEterna Zentaris Inc. - Lixte Biotechnology Holdings, Inc. - Lorus Therapeutics Inc. - Novogen Limited - Threshold Pharmaceuticals, Inc. - Sareum Holdings plc - MabVax Therapeutics, Inc. - Bionucleon Srl - CerRx, Inc. - Merrimack Pharmaceuticals, Inc. - Neotropix, Inc. - APEIRON Biologics AG - Xcovery, Inc. - Sutro Biopharma, Inc. - Incuron, LLC - Errant Gene Therapeutics, LLC - DEKK-TEC, Inc. - Bexion Pharmaceuticals, LLC. - Cancer Prevention Pharmaceuticals, Inc. - CureFAKtor Pharmaceuticals. LLC For more information visit http://www.researchandmarkets.com/research/9p...roblastoma
Endometrial Cancer - Pipeline Review, H1 2014: 24 Company and 37 Drugs Profiled
M2 - Wed May 07, 9:00AM CDT
Research and Markets (http://www.researchandmarkets.com/research/w7hgnd/endometrial) has announced the addition of the "Endometrial Cancer - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Endometrial Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Endometrial Cancer and special features on late-stage and discontinued projects. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Companies Involved: - AEterna Zentaris Inc. - Acceleron Pharma, Inc. - ArQule, Inc. - Ariad Pharmaceuticals, Inc. - Arno Therapeutics, Inc. - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - Critical Outcome Technologies Inc. - Eisai Co., Ltd. - Esperance Pharmaceuticals, Inc. - Exelixis, Inc. - Galena Biopharma, Inc. - GlaxoSmithKline plc - Igenica, Inc. - ImmunoGen, Inc. - Ipsen S.A. - Merck & Co., Inc. - Novartis AG - OncoHoldings, Inc. - Oryzon Genomics S.A. - Pfizer Inc. - Pharmsynthez - Scancell Holdings Plc - Taiho Pharmaceutical Co., Ltd. Drug Profiles: - zoptarelin doxorubicin - ixabepilone - lenvatinib - MK-2206 - PF-05212384 - ridaforolimus - dalantercept - cabozantinib (s)-malate - nintedanib - EP-100 - dovitinib lactate - buparlisib hydrochloride - Virexxa - GALE-301 - GSK-2636771 - GSK-2141795 - GSK-2256098 - GSK-2141795 trametinib - IMGN-853 - ARQ-092 - onapristone ER - COTI-2 - EP-200 - ONCO-101 - TAS-2985 - SERD 2 - (ponatinib ridaforolimus) - Virexxa - Monoclonal Antibody For Endometrial Cancer - Small Molecules for Oncology and Infectious Disease For more information visit http://www.researchandmarkets.com/research/w7hgnd/endometria
Aeterna Zentaris to Present Poster on New Therapeutic Opportunities in Oncology with Erk Inhibitors at AACR Meeting in San Diego
CNW Group - Tue Apr 01, 6:30AM CDT
Aeterna Zentaris Inc. (NASDAQ: AEZS, TSX: AEZ) (the "Company"
today announced that a poster will be presented on AEZS-134, a highly potent and selective ATP competitive Erk inhibitor, during the American Association for Cancer Research (AACR) Annual Meeting, which will be held April 5-9, 2014 in San Diego, California. 
